Erk associates with and primes GSK-3β for its inactivation resulting in upregulation of β-catenin

401Citations
Citations of this article
157Readers
Mendeley users who have this article in their library.

Abstract

β-catenin is upregulated in many human cancers and considered to be an oncogene. Hepatocellular carcinoma (HCC) is one of the most prevalent human malignancies, and individuals who are chronic hepatitis B virus (HBV) carriers have a greater than 100-fold increased relative risk of developing HCC. Here we report a mechanism by which HBV-X protein (HBX) upregulates β-catenin. Erk, which is activated by HBX, associates with GSK-3β through a docking motif (291FKFP) of GSK-3β and phosphorylates GSK-3β at the 43Thr residue, which primes GSK-3β for its subsequent phosphorylation at Ser9 by p90RSK, resulting in inactivation of GSK-3β and upregulation of β-catenin. This pathway is a general signal, as it was also observed in cell lines in which Erk-primed inactivation of GSK-3β was regulated by IGF-1, TGF-β, and receptor tyrosine kinase HER2, and is further supported by immunohistochemical staining in different human tumors, including cancers of the liver, breast, kidney, and stomach. Copyright ©2005 by Elsevier Inc.

Cite

CITATION STYLE

APA

Ding, Q., Xia, W., Liu, J. C., Yang, J. Y., Lee, D. F., Xia, J., … Hung, M. C. (2005). Erk associates with and primes GSK-3β for its inactivation resulting in upregulation of β-catenin. Molecular Cell, 19(2), 159–170. https://doi.org/10.1016/j.molcel.2005.06.009

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free